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PENILAIAN HUBUNGAN ANTARA EKSPRESI LATENT MEMBRANE 
PROTEIN 1 (LMP-1) VIRUS EPSTEIN-BARR DENGAN PROTEIN 
PEMULIHAN DNA DALAM KANSER NASOFARINKS 
ABSTRAK 
 
Kanser nasofarinks (NPC) adalah kanser ketiga tertinggi di kalangan lelaki di 
Malaysia. Kanser ini adalah unik dari pelbagai aspek terutamanya hubung kait antara 
penyakit ini dengan virus seperti virus Epstein-Barr (EBV). LMP-1 adalah protein 
onkogen utama EBV. LMP-1 mengawal rangkaian ekpresi yang menyebabkan 
ketidakaturan pertumbuhan sel. Oleh sebab itu, LMP-1 telah dianggapkan berpotensi 
dijadikan sasaran terapi kanser. Bukan kesemua kanser nasofarinks akan menunjuk 
ekspresi LMP-1 kerana ekspresi LMP-1 dipercayai diregulasi dalam kanser. Kajian 
menunjukkan protein pemulihan DNA adalah dikaitkan dengan proses 
karsinogenesis maka protein pemulihan DNA dianggap mustahak dalam konteks ini. 
Kajian dari merata dunia telah menunjukkan kes koinfeksi Human papillomavirus 
(HPV) dalam kanser nasofarinks tetapi status di Malaysia masih tidak diketahui. 
Dalam kajian ini, kepentingan koinfeksi dalam kanser nasofarinks telah dikaji. Lima 
puluh tujuh (57) kes kanser nasofarinks dan dua puluh tujuh (27) kes normal dari 
Kelantan telah dimasukkan dalam kajian ini. Ekspresi protein pemulihan DNA 
seperti ATM, DNA-PKcs, Ku70, Ku86 dan caspase-3 telah dikaji dengan kaedah 
immunohistokimia. Status infeksi virus pula dikaji dengan menggunakan tindak 
balas rantai polimerase (PCR). Hasil kajian menunjukkan korelasi positif diantara 
eskpresi LMP-1 dengan ATM dan caspase-3 aktif. Hasil kajian juga menunjukkan 
bahawa HPV adalah dikaitkan dengan peningkatan ekspresi ATM dan penurunan 
ekpresi Ku86. Selain itu, hasil kajian juga menunjukkan bahawa LMP-1 dan HPV 
xiv 
 
mungkin bekerjasama dalam mengawalatur ekpresi protein. Kajian yang menunjukan 
infeksi EBV dalam kes normal dan pengaruh infeksi HPV menunjukkan 
kemungkinan EBV hanya memainkan peranan yang utama atau sambilan dalam 
kanser nasofarinks. Oleh itu, hasil kajian mencadangkan LMP-1 mempengaruhi 
ekspresi protein pemulihan DNA.  
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EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1 (LMP-1) 
EXPRESSION AND ITS ASSOCIATION WITH EXPRESSION OF DNA 
DAMAGE REPAIR PROTEINS IN NASOPHARYNGEAL CARCINOMA 
(NPC) – AN EVALUATION 
ABSTRACT 
 
Nasopharyngeal carcinoma (NPC) is the third most occurring cancer in Malaysian 
males, and is unique in its association with Epstein-Barr virus (EBV). LMP-1 is the 
major oncogenic protein of the EBV. EBV LMP-1 acts by constitutive regulation of 
host signalling pathways leading to dysregulated cell growth and has been considered 
a potential therapeutic target for LMP-1 expressing tumours. LMP-1 is thought to be 
regulated in its expression as it is not expressed in all NPC tumours. DNA repair 
proteins are of importance in this context as the status of the function of these 
proteins has been linked to the process of carcinogenesis. Studies world-wide have 
shown co-infection of NPC by Human papilloma virus (HPV). The status in 
Malaysia is not known. In the present study, the importance of viral co-infection in 
NPC and how it influences the expression of the EBV and host proteins has been 
evaluated. Fifty seven (57) NPC and twenty seven (27) benign adenoid samples from 
State of Kelantan in Malaysia were included in this study. Expression of DNA repair 
proteins such as ATM, DNA-PKcs, Ku70, Ku86, pro and active caspase-3 protein 
were evaluated immunohistochemically. The viral status of the lesions was evaluated 
using PCR on extracted DNA from the tumour/benign tissues. Results showed that 
LMP-1 expression showed a positive correlation with the expression of ATM, and 
active caspase-3. No correlation was observed with the expression of other DNA 
repair proteins. In the present study, it was observed that HPV infection was 
xvi 
 
associated with increased ATM expression and decreased Ku86 expression. It was 
also observed that LMP-1 and HPV may work synergistically in altering the host 
protein interaction as seen in the different groups of lesions. The observation of a 
number of EBV positive non-cancerous lesions in this study and the influence of 
HPV infection give credence to the hypothesis that EBV might only play a main or 
casual role in NPC. These results thus suggest that LMP-1 influences the expression 
of host DNA damage repair proteins. 
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CHAPTER ONE 
INTRODUCTION 
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INTRODUCTION 
 
1.1 Cancer 
Cancer, also known as malignant neoplasm, refers to disease characterized by an 
uncontrolled growth and division of cells, and the ability of cells to invade and 
metastasise locally or at the other parts of the body. Cancer formation can be due to 
multiple causes. One major reason for formation of cancer is the damage and 
mutation of DNA, on the gene coding for protein which is essential for monitoring 
cell growth and death (proto-oncogene), with certain genes transforming into 
oncogenes. Oncogene activation causes unusually high expression of normal or 
altered proteins (oncoprotein), resulting in uncontrolled cell growth and death. 
Cancer can also be caused by infectious agents such as bacteria and viruses. Viruses 
have the ability to alter the genetic configuration of the cells. Viruses are known to 
activate oncogenes which increase the risk of cancer formation. Viruses have been 
accepted widely as the second most important risk factor for human cancer formation, 
surpassed only by tobacco use (zur Hausen, 1991). The transformation of a cell into a 
cancer cell is accompanied by alterations in protein expression, behavior, and 
morphological features such as size and shape of cell and nucleus. At this stage, the 
cancer cell is distinguishable from its normal counterpart.  
 
1.1.1 Cancer and viruses 
In 1908, Oluf Bang and Vilhelm Ellerman demonstrated that avian erythroblastosis 
could be transmitted by cell-free extracts, initiating the theory that cancer can be 
caused by viral particles (Ellermann and Bang, 1909). Since then, many viruses have 
been identified to be associated with cancer formation. In 2002, it was estimated that 
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17.8% of cancer worldwide was caused by infections, with around 12% being caused 
by human tumour viruses. The frequency was higher in developing countries (26.3%) 
as compared to that in developed countries (7.7%) further supporting the hypothesis 
of a relationship of cancers with infections (Parkin, 2006).  
Viral carcinogenesis follows several direct mechanisms that involve the introduction 
of viral oncogenes, enhancement of cell proto-oncogenes, and the inactivation of 
tumour suppressor genes. Viruses can also contribute to oncogenicity indirectly, by 
reducing host immunity (such as in the case of HIV), inactivating host proteins (HPV 
and EBV associated cancers) and chronic nonspecific inflammation occurring over 
long time span of infection, such as in the case of HCV-induced liver cancers. In the 
context of DNA virus, virus transforms the cell by integration of viral genome into 
the host genome. Introduced viral oncogenes modify cellular gene expression 
patterns to suit the proliferation and spread of the virus. In the process, a number of 
host protective mechanisms are affected which may lead to cancers.  
Recent studies show that in the case of most virus-induced cancers, infection by a 
single virus per se is not sufficient for induction of the cancer but requires promoting 
and interacting effects of either other viruses or factors related to environment, 
genetic susceptibility or habits (Danaei et al., 2005). For example, HIV-HBV and 
HIV-HCV co-infection cause liver cancer development (Hu and Ludgate, 2007). 
Besides this, it has also been found that EBV and Plasmodium falciparum co-
infection can cause endemic Burkitt’s Lymphoma (Moormann et al., 2011). HHV-8 
and HIV co-infection were also implicated in the development of Kaposi’s sarcoma 
(Pyakurel et al., 2007). In the case of EBV-associated cancers, it is clear that EBV 
infection alone is not sufficient to cause nasopharyngeal cancers (Chang and Adami, 
2006). It is a known fact that more than 90% of the adults worldwide are infected 
4 
 
with EBV with a very small proportion of them developing NPC. This point towards 
the role of other factors in the causation of NPC. HPV has been reported to be a 
candidate with highest probability in this process at least in a proportion of NPCs. 
This study mainly focuses on effect of Epstein-Barr virus (EBV), the virus known to 
be associated with Nasopharyngeal Carcinoma, the LMP-1 protein which is the 
major oncogenic protein of the EBV and co-infection by Human Papilloma Virus 
(HPV) in NPCs from Kelantan state. 
 
1.2 Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma is a tumour that arises from the epithelial cells that 
covers the surface and line the nasopharynx. NPCs are classified into three subtypes 
by the World Health Organisation, i.e. Type I: Keratinizing squamous cell carcinoma, 
Type II: non-keratinizing carcinoma and lastly Type III: undifferentiated carcinoma. 
Nasopharyngeal carcinoma occurs in all age groups, with increasing incidence after 
the age of 30 years. It is a rare tumour in most parts of the world (Table 1.1). 
However, it is endemic in parts of Asia, especially Southern China and South East 
Asia. In Peninsular Malaysia, it is the third most frequent male cancer found, 
accounting for up to 8.4% of total cancers (Figure 1.1). As per the National Cancer 
Registry data, the Chinese had the highest incidence with an age standardized 
incidence (ASR) of 10.9 in males and 3.5 in females, followed by the Malays and the 
Indians. In comparison with other countries, ASR of Malaysian Chinese males and 
females ranked second after Hong Kong (Omar and Tamin, 2011). The hospital 
record in USM Hospital shows the cancer to be also prevalent in individuals 
belonging to Malay and Indian ethnicity (unpublished data). The report on 
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investigations from Sarawak in Malaysia shows the incidence in the people 
belonging to the Bidayuh community to be the highest in the world (Devi et al., 
2004).  
Treatment of NPC includes chemotherapy and radiotherapy (Brennan, 2006). 
Although NPC is highly sensitive to radiotherapy with good control of the primary 
tumour, distant metastases are very frequent (Jereb et al., 1980), the reason for which 
is not yet clear. The high sensitivity of the tumour to radiation and the high rate of 
recurrence point towards defects in the DNA damage repair mechanisms of the host. 
Nasopharyngeal carcinoma has been generally associated with EBV (Macsween and 
Crawford, 2003). Several EBV proteins and also DNA have been detected in the 
NPC tissues and serum of patients (Wolf et al., 1973, Krishna et al., 2004, Yap et al., 
2007) which point towards the strong association between NPC and EBV infection. 
Majority of the undifferentiated type of NPCs are reported positive for EBV, while a 
number of reports show some of the lesions to be positive for Human papillomavirus 
(HPV) (Lo et al., 2010). Other than EBV infection, an increased susceptibility for 
NPC is also reported to be brought about by multiple factors such as ethnicity and 
environmental factors (Bailey et al., 2006).  
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Table 1.1: Global incidence rate of nasopharyngeal carcinoma (Chang and Adami, 
2006) 
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Figure 1.1: Ten most frequent cancers in males, peninsular Malaysia 2007 (Omar and 
Tamin, 2011) 
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1.2.1 Histopathology 
Histologically, NPC has been classified into three types. 
 Keratinizing squamous cell carcinoma (KSCC) 
 Non-keratinizing squamous cell carcinoma (NKSCC) 
 Undifferentiated carcinoma (UDC) 
Of the three varieties, UDC is the most common one. It consists of uniform cells with 
a poorly defined cytoplasmic border that gives the tumour a syncytial appearance. 
The nuclei are pale and rounded in shape, with a distinct nuclear edge and multiple 
prominent eosinophilic nucleoli. Tumour cells generally form trabeculae or solid 
sheets, and mitosis is common. Small lymphocytes which are usually seen between 
tumour cells, resulted in the name lymphoepithelioma or ‘schminke tumours’ as a 
synonym for NPC in the past. Epithelial origin of the tumour has been confirmed by 
the observation of desmosomes by electron microscopy and cytokeratin positivity by 
immunohistochemistry, enabling to distinguish NPC from malignant lymphoma. 
Keratinizing and non-keratinizing forms of NPC have a more conventional 
appearance, with intercellular bridges/prickles and a squamous epithelial pattern with 
flattened cells superficially or keratin pearls (Ramsay, 1992). 
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1.2.2 WHO classification 
NPC has been classified by World Health Organization (WHO) into three categories 
based on the histopathological classification.  
 WHO type I – Keratinizing squamous cell carcinoma with various degrees of 
differentiation and similar to carcinoma that derived from other sites of the 
head and neck. 
 WHO type II – Non Keratinizing epidermoid carcinoma 
 WHO type III – Undifferentiated carcinoma or lymphoepithelioma. It has 
tumour infiltration with T lymphocytes which themselves are not malignant. 
It is also the most common form. 
WHO type II and type III are frequently grouped as Undifferentiated Carcinoma 
Type (UNCT) (Wenig, 1999). The histological type may be of prognostic 
significance with UNCT having a higher local control rate after treatment with 
radiotherapy (RT) than KSCC. UNCT is also shown to fail more distally than locally. 
 
1.2.3 Spread of tumour 
NPC can remain asymptomatic and undiagnosed for a long time due to its 
inaccessibility. It has a marked potential for invasion and metastasis, and hence most 
patients present with locally or regionally advanced disease. Major adverse 
prognostic factors of NPC are age older than 40 years at the time of diagnosis, 
advanced TNM stage, skull based invasion and facial bone invasion (Farias et al., 
2003). NPC is often submucosal. It can spread submucosally without marked 
projection into the nasal cavity. NPC has a predictable and orderly development of 
cervical metastasis. Bilateral lymphatic spread is usually very common as 
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nasopharynx is a midline structure. Systemic spreading occurs by blood stream. The 
most common site of spread is lung, followed by bone. Bulky primary tumour is 
more prone to metastasis and nodal status is used as a predictive marker of eventual 
development of distant metastasis. 
 
1.2.4 Staging 
Clinical staging of NPC begins with physical examination such as evaluation by 
nasopharyngoscopy. Radiographic assessment is also carried out to recognize the 
extent of primary and lymph node involvement. Magnetic resonance imaging (MRI) 
is used to find out invasion of muscles, nerves or intracranial extension. The 
International Union Against Cancer/American Joint Committee on Cancer 
Nasopharynx Staging System uses the primary tumour (T1-T4), lymph nodes (N0-
N3), and systemic metastasis (M0-M1) classification which is widely used in most 
countries (Table 1.2) (Liu et al., 2008).  
Table 1.2: Staging grouping (UICC – 1997) 
Stage Primary 
tumour 
Lymph 
node 
Systemic 
metastasis 
0 TIS N0 M0 
I T1 N0 M0 
IIA T2a N0 M0 
IIB T1 N1 M0 
 T2a N1 M0 
 T2b N0,N1 M0 
III T1 N2 M0 
 T2a, T2b N2 M0 
 T3 N0-2 M0 
 T3 N0-2 M0 
IVA T4 N0-2 M0 
IVB Any T N3 M0 
IVC Any T Any N M1 
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1.2.5 Metastasis 
Metastasis is one of the primary features of malignant tumours. It is governed by a 
group of proteinases that degrade the extra cellular component. In metastasis, tumour 
cells first leave the primary site and invade the local host tissue followed by entry 
into the circulation and arrest at a distant vascular bed. Then, extravasation of the 
tumour cells into the target organ and proliferation as a secondary colony takes place. 
Invasive potential of tumour has important prognostic significance.  
It has been suggested that EBV induces metastatic factors in NPC via the LMP-1. 
LMP-1 was shown to directly contribute to metastasis (Horikawa et al., 2007). 
Studies have reported that the presence of EBV DNA in the peripheral blood of NPC 
patients indicate higher risk of developing distant metastasis as well as a lower 
survival rate (Lin et al., 2001). Other viruses have also been reported to induce 
metastatic potential. An example in this context is that of HPV. Besides this, HPV 
was also identified in tonsillar squamous cell carcinoma with regional metastases 
(Strome et al., 2002).  
 
1.2.6 Recurrence 
Early stage NPC is highly curable with radiotherapy. However, most of the patients 
with NPC have late stage disease at presentation (Abdullah et al., 2009). A high 
incidence of loco-regional recurrences has been reported in NPC. Majority of the 
loco-regional recurrences develop within 3 years after radiation therapy outside or at 
the margin of the treatment portal. However, recurrences have also been observed 
after a long latent period (Li et al., 2012). Distant metastases also frequently occur 
within 3 years after treatment. The most common site for distant metastases is the 
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bones, liver or the lungs (Lu et al., 2009). Frequent follow up examination is 
important because some of the loco-regional and distance recurrences can also 
appear between 6 and 10 years (Nozaki et al., 1998). It is hypothesized that the high 
incidences of late recurrence in NPCs could be due to a defective DNA repair 
mechanism in the host. High levels of abnormal DNA repair function in the cells 
could increase the resistance of the cells to treatment and also DNA repair-mediated 
genomic and chromosomal instability. Studies have shown close associations 
between members of DNA repair proteins and recurrence both in NPCs and other 
cancers (Wang et al., 2010, Silva et al., 2010, Goode et al., 2002). 
 
1.2.7 Treatment 
Radiotherapy (RT) is the mainstay of treatment and it may or may not be followed 
with Chemotherapy (CT). Five years overall survival rates following radiotherapy 
are stage dependent and it can range from 70% to 80% for stage I, and 20% to 40% 
for stage IV. Most of the NPC recurrences are observed in the first 2 years after 
therapy and it can manifest loco-regionally or systemically or both (Yamazaki et al., 
2011).  
 
1.2.8 Influence of environmental factors in nasopharyngeal carcinoma 
NPC presents with interesting epidemiologic and biologic characteristics. NPC is 
endemic in particular populations in specific geographic regions. The endemic areas 
include southern parts of China and South-East Asia. NPCs that occur in endemic 
areas are usually of WHO Type II or III. In United States of America and Western 
Europe, it often occurs as WHO Type I and is mostly related to exposure to the 
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typical head and neck cancer risk factors, such as the exposure to alcohol and 
tobacco. Epidemiological studies have implicated the nasopharynx as a tobacco 
susceptible cancer site. It is also thought that NPC can be influenced by diet. 
Cantonese-style salted fish which is a common food in local diet is thought to be an 
etiological factor for NPC. Several case control studies conducted in diverse 
populations in different parts of Asia and Europe have confirmed the link between 
diet and NPC (Polesel et al., 2012, Yu et al., 1989). A direct link between the 
carcinogenic substances such as nitrosamines, genotoxic and EBV activating 
substances in preserved food such as salted fish and the occurrence of NPC has also 
been reported in a number of studies in humans and cell cultures (Shao et al., 1988, 
Ward et al., 2000, Yu et al., 1986).  
 
1.3 Epstein-Barr virus 
Epstein-Barr virus (EBV), also known as Human herpesvirus 4 belongs to 
Herpesviridae family of virus which is the primary cause of infectious 
mononucleosis. It is the first human cancer-causing virus discovered by Anthony 
Epstein, Bert Achong and Yvonne Barr from Burkitt’s lymphoma cells nearly 50 
years ago (Epstein et al., 1964). EBV is one of the most common viruses which 
infects human, often after initial asymptomatic subclinical infection (Pathmanathan, 
1993). Ninety five percent of adults between 35 and 40 years of age world-wide are 
infected by EBV (Chang and Adami, 2006). Primary EBV infections in third world 
countries typically occur in early childhood and are sub-clinical. In Hong Kong, 
nearly 80% of the children are EBV positive by age 10 and 100% by adulthood 
(Humans, 2004). The virus remains latent for a long time and is associated with 
development of several cancers including NPCs later in life. Transmission is mainly 
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through saliva in the developing countries where there is crowding and lack of 
hygiene. On the contrary, in more developed countries, primary infections occur at a 
later age and may present as acute infectious mononucleosis (CDC, 2006). The 
infected B cells remain in the circulatory system avoiding detection by both cellular 
and humoral immune system (Kurth et al., 2000). The infected B cells do not 
differentiate further: it remains in an intermediate (proliferative) stage without 
differentiating into antibody producing plasma cells. However, it is believed that 
infected B cells are responsible for spreading EBV infection to tissues and organs of 
the body. IgG and IgM antibodies, appear early in response to the viral capsid 
antigen (VCA) followed by antibodies to early antigen (EA) that appear three or four 
weeks after the onset of the illness and finally against the Epstein-Barr Nuclear 
Antigen (EBNA) component of the virus (Henie et al., 1974).  
EBV was thought to be evolved from non-human primate origin. It has similar 
sequences and genetic organization with EBV-like viruses of chimpanzees and 
rhesus monkeys, and they infect only B cells and epithelial cells of primate origin 
(Cohen, 2000). The route of entry of EBV into epithelial cells still remains vague. 
EBV first binds the viral envelop glycoprotein gp350/220 to the cellular complement 
receptor CD21 or CR2. The viral protein gp42 binds to a HLA class II co-receptor on 
the host cell. Cell to cell contact is thought to be the mechanism for the infection of 
epithelial cells by EBV (Knox and Young, 1995). EBV is believed to initiate the 
infection in human epithelial cells of the oropharynx which is suitable for viral 
replication. After the primary infection, EBV can diffuse across the basal membrane 
and cause latent infection in B lymphocytes. B lymphocytes migrating through the 
throat are latently infected and are thought to be the source of continued virus spread 
due to low level of spontaneous virus replication in B cells, leading to reinfection of 
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epithelial cells. This infection is the central cause of infection in distal normal 
epithelial surfaces such as nasopharynx and frequent shedding into the saliva. This 
persistent and active lytic infection can remain for many years (Thompson and 
Kurzrock, 2004).  
EBV positivity has been frequently reported in normal nasal mucosa. Chen et al. 
detected 8.4% EBV positivity in epithelia of non-tumour nasopharyngeal biopsies 
(Chen et al., 1996). It was found that nasal polyps, the etiology of which is not very 
clear, carry EBV DNA in 69- 85% of the cases (Tao et al., 1996). EBV has also been 
detected by PCR in 80% of normal nasopharyngeal tissue in asymptomatic Chinese 
individuals, 8.3% of normal oral mucosa and 77.8% of oral premalignant lesions 
(Tao et al., 1995, Cheung et al., 1993). In the humans, EBV is capable of infecting B 
lymphocytes, squamous epithelial cells, glandular epithelial cells, myoepithelial cells, 
smooth muscle cells, T cells, NK cells, plasma cells, and follicular dendritic cells 
(Gulley and Tang, 2008). EBV can often be cultured from the pharynx of most 
asymptomatic individuals. The presence of replicating virus in hairy cells of oral 
leukoplakia, a benign disease of the oral cavity, usually found in HIV patients and in 
NPC, coupled with the productive infection of epithelial cells in culture, suggest that 
epithelial cells could have an important role to play in EBV infection (Faulkner et al., 
2000). Healthy adults, however, harbour the virus in the B cells and usually do not 
produce the oncogenic proteins. It should be noted that PCR analysis does not 
discriminate between the tissue types and hence the EBV positivity remains high in 
normal tissues even when the EBV infection is limited to the lymphoid cells.  
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1.3.1 EBV genome 
EBV is a double stranded DNA virus. EBV genome consists of 172 kbp linear DNA 
molecules which consist of 0.5 kbp terminal repeats and numerous internal repeats 
separated by unique areas. EBV executes two major programs which are lytic cycle 
or latent cycle, each with its own objectives. In lytic cycle the objective is to produce 
infectious virions, while in latent cycle it does not result in production of virus 
particles. Around 100 viral proteins are expressed during lytic cycle but only a 
limited and distinct set of viral proteins are expressed in the latent cycle which 
include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, 
EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-
1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs) (Kieff and 
Rickinson, 2007). EBV genome is also found to code for more than twenty 
microRNAs (Grundhoff et al., 2006). There are at least three programs present in a 
latent cycle; Latency I, II and III, as reported in Burkitt's lymphoma cell lines 
(Calderwood et al., 2007b). 
 
Table 1.3: EBV proteins expressed in latent cycles  
 
Programs Viral proteins expressed 
Latency I EBER1&2 EBNA1    
Latency II EBER1&2 LMP2A LMP2B EBNA1 LMP1 
Latency III EBER1&2 LMP2A LMP2B EBNA1 LMP1 EBNA2,3,4,5,6 
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1.3.2 NPC and Epstein-Barr Virus 
EBV has been closely associated with human cancers, including Burkitt’s lymphoma, 
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and nasopharyngeal carcinoma. 
Epstein-Barr Virus (EBV) belongs to the family herpesviridae and was the first virus 
identified to be associated with human cancers. Epstein-Barr Virus is consistently 
detected in nasopharyngeal carcinoma (Niedobitek, 2000), especially in the WHO 
type III non-keratinizing undifferentiated type. Elevation of serum IgA to EBV virus 
capsid antigen (VCA) is often detected before the development of NPC by several 
years, suggesting that EBV reactivation and replication occurs before the beginning 
of NPC development (Ji et al., 2007). EBV establishes latent infection in its host and 
persists lifelong and the proteins produced by these viruses affect the host protein 
functioning. As much as 173 interactions between EBV and human proteins have 
been identified (Calderwood et al., 2007a).  
EBV viral genome is clonal in dysplastic cells as demonstrated by homogenous 
number of terminal repeat elements and cells in carcinoma in situ, demonstrating that 
the tumour originated from a single infected cell (Raab-Traub and Flynn, 1986). It 
also suggests that EBV infection is an early event in the multi-step progression of 
NPC. The consistent presence of EBV in pre-invasive and tumour cells of EBV 
associated cancers, especially in the case of NPC, makes it useful as a marker for 
NPC and also for detecting NPC risk in high risk individuals (Yu et al., 2011). An 
increase in EBV specific antibody titre after therapy for NPC is associated with a 
poor prognosis and a declining or constant level of antibody is associated with a 
better prognosis. Undifferentiated NPC is most consistently associated with EBV 
regardless of its geographical origin despite the fact that EBV infection is ubiquitous. 
18 
 
While EBV is believed to be involved in the development of NPC, its infection alone 
is inadequate to start the tumorigenesis of NPC.  
EBV is known as the etiologic agent of acute infectious mononucleosis, and it is 
strongly associated with Burkitt’s lymphoma and undifferentiated NPC. EBV is also 
associated with other diseases such as EBV associated hemophagocytic syndrome, 
chronic active EBV infection, T-cell lymphoma, natural killer cell lymphoma, 
lymphoproliferative disease in immune-compromised hosts, Hodgkin’s disease, 
pyothorax-associated B-cell lymphoma and smooth muscle tumours and in other 
cancers such as gastric carcinoma and primary invasive ductal breast cancer. The 
detection of EBV viral DNA and also its nuclear antigen in tumours, especially in 
nasopharyngeal carcinoma, has revealed that EBV can infect epithelial cells and 
could contribute with the transformation to cancer (Thompson and Kurzrock, 2004). 
EBV clonal genome is evident by the homogenous number of terminal repeat 
elements, and it is found in cells in pre-invasive lesions suggesting that it is directly 
involved in the process of cell transformation (Neri et al., 1991).  
 
1.4 Human Papilloma Virus 
Human Papilloma Virus is a double stranded DNA virus from the family of 
Papillomaviridae. It has been associated with a number of diseases and conditions 
such as skin warts, genital warts and also cancers such as those of the uterine cervix, 
oral cavity, tonsil, and penis. There are more than 100 types of HPV that have been 
identified based on their genomic sequences (Morbini et al., 2012). HPV infect and 
replicate only in the basal cells of stratified epithelium (Schiller et al., 2010).  
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In benign lesions, HPV present as a multiple copy episome. While in the malignant 
lesions, the HPV DNA is integrated into the host genome. The papilloma virus life 
cycle differs from other virus in such a way that they are the only viruses that begin 
their infectious process at an extracellular site. First, the virus binds its L1 major 
capsid protein to heparan sulfate proteoglycans (HSPGs) on segments of the 
basement membrane (BM) that are exposed after epithelial trauma. The 
conformational change exposes the N-terminus of L2 minor capsid protein to furin 
cleavage. L2 proteolysis reveals a previously obstructed surface of L1. It binds to an 
unknown cell surface receptor on keratinocytes that have migrated over the basement 
membrane to close the wound (Schiller et al., 2010). The whole infectious process is 
slow and takes up to 12 – 24 hours before the start of transcription. The infection 
requires the availability of epidermal or mucosal epithelial cells that are still able to 
proliferate (basal layer cells) (Hoffmann et al., 2006). Specific early genes such as 
E5, E6 and E7 are expressed resulting in heightened proliferation and the lateral 
expansion of the infected cells (Boulenouar et al., 2010). Late viral gene expression 
is initiated following the entry into the suprabasal layers. Viral genome is then 
replicated followed by production of structural proteins. Complete viral particles are 
assembled and released in the upper layers of the epidermis or mucosa (Figure 1.2). 
HPV persist in the basal cells for long periods. It does not cause cells in the basal 
layer to lyse since the production of the virus is restricted to the suprabasal cells.  
Humans are the only known reservoirs of HPV. Viral transmission occurs through 
direct physical contact or by contaminated surfaces. HPV only replicates in 
terminally differentiated epithelial cells and diagnosis of infection through tissue 
culture has not been possible (CDC, 2012). Both normal epithelia, epithelia in benign 
lesions and cancer lesions have been reported to be infected by HPV.  
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Figure 1.2: HPV life cycle (Stanley, 2012) 
 
 
 
1.4.1 HPV genome 
HPVs are double stranded, circular DNA viruses that exist as a nuclear episome in 
infected cells. It is classified into subgroups based on the infection sites - cutaneous 
or mucosal epithelia. Mucosal HPVs are further classified into high risk (HPV-16, -
18, -31, -45), intermediate risk (HPV-33, -35, -39 and others) and low risk (HPV-6, -
11) types. It is classified based on their epidemiologic association with cancer and 
benign epithelial hyper-proliferation (zur Hausen, 1996). HPV genome consists of 
7900 bp of double stranded circular DNA and it is divided into eight open reading 
frames, i.e. E6, E7, E1, E2, E4, E5 and L2 and L1 - coding for early (E) or late (L) 
functions (Ault, 2006). HPV integrates its genome into host cell DNA in the course 
of cancer development. The ring molecules are most often opened within the E2 
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open reading frame, disturbing the gene continuity. Some part of open reading frame 
are regularly deleted after integration, i.e. part of E2 and open reading frames that are 
adjacent to E2 - E4, E5 and part of L2.  
 
1.4.2 Role of HPV in cancer 
HPV infections have been associated with more than 5% of cancers. HPV has been 
associated with predominantly the cancer of uterine cervix, carcinoma of the 
anogenital tract, vagina, penis, and anus and some head and neck cancers such as 
those of oropharynx and nasopharynx. It is estimated that HPV in HNSCC range 
from 25 - 70% or more with different rates for different anatomic regions of the head 
and neck and different geographic regions (Thibaudeau et al., 2013). For example, its 
incidence in laryngeal carcinomas ranges from 4-20% and 100% in verrucous 
laryngeal carcinomas (Gillison et al., 1999, McKaig et al., 1998). Its prevalence rate 
in oral cavity is estimated to range between 35-80%. HPV associated squamous cell 
carcinoma has been identified in 80% cases of oral leukoplakia and 46% of cases of 
carcinomas of tongue and floor of mouth (Maitland et al., 1987, Betiol et al., 2012). 
HPV positivity has also been reported in carcinomas of the sinonasal tract. Bishop et 
al. reports an incidence of 21% positivity in sinonasal carcinomas (Bishop et al., 
2013). In Malaysia, the study carried out in state of Kelantan showed 51.4% HPV 
positivity among oral cancers (Saini et al., 2011).  
In the case of cervical cancer, the most frequently associated are HPV 16 and 18 
types. In peninsular Malaysia, cervix cancer burden is reported to be 12.2 
cases/100,000 populations. The incidence of this cancer has been reported to be 
higher in the Malay population (49.8%) followed by the Chinese (34.2%) and 
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Indians (11.3%) (Aljunid et al., 2010). The HPV infection rate was reported to be 
100% in cervix cancer lesions and 92% in intraepithelial lesions in women from 
areas serviced by the Universiti Kebangsaan Malaysia Medical Centre in Kuala 
Lumpur (Sharifah et al., 2009). The prevalence of HPV infection in the 10 normal 
smears was not reported in the study by Sharifah et al. Wong and Sam reported from 
Women in Selangor, Malaysia an incidence of 46.7% in non-cancerous women 
pointing towards a high incidence of HPV in Malaysian individuals. However, the 
results are not reflective of Malaysia as a country due to the lack of awareness, 
resources and infrastructure especially in rural areas which has led to low rates of 
screening. The estimated screening rate was only about 6% of women in Malaysia 
(Wong and Sam, 2007). Resistance towards Pap tests has been contributed by the 
health policies, cultural inhibitions and misperceptions regarding the disease as well 
as the screening procedure (Wong and Sam, 2007).  
HPV infection is also associated with benign lesions and normal epithelium in the 
upper airway, including focal epithelial hyperplasia, inverted nasal papillomas and 
onset benign respiratory papillomatosis. The sharing of similar non-keratinising 
characteristics with the cervix epithelia is thought to be a factor for attracting HPVs 
to the epithelia in the head and neck region, larynx and some other organs 
(Franceschi et al., 2011). Gonzales et al. have reported HPV infection as high as 91% 
in HPV associated oral benign lesions with Duray et al. from Belgium reporting 77% 
of the laryngeal benign lesions to be positive for HPV (Gonzalez et al., 2007, Duray 
et al., 2011). The HPV incidence rate in adenoid lesions from Turkey has been 
reported to be about 6% (BALOĞLU et al., 2010). The two Malaysian studies 
reporting the HPV prevalence in 105 normal oral epithelium from the state of 
Kelantan (Saini et al., 2010) and in non-cancerous smears from Selangor (Chong et 
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al., 2010) of 24.8% and 46.7% respectively point towards the high HPV prevalence 
rate in the Malaysian population. The global incidence of HPV is estimated to be 
about 10% in the normal population (Bruni et al., 2010).  
Table 1.4: Detection of HPV in normal oral lesions 
 
Author & Year Number of normal cases % HPV +ve 
Woods et al. (1993) 9 67.00% 
Nagpal et al. (2002) 26 26.90% 
Chen et al. (2002) 29 37.90% 
Zhang et al. (2004) 40 55.00% 
Terai et al. (1999) 37 81.10% 
Sanchez-Vargas et al. (2010) 46 72.00% 
Tominaga et al. (1996) 3 100.00% 
 
 
 
1.5 Viral co-infection in cancer lesions 
Viral co-infection is a state where two or more types of viral particles simultaneously 
infect a single cell. Viral co-infection has been a field of interest due to the 
complication it can bring to the patient disease state. This can be shown in the case of 
various viral co-infection such as HIV (Human Immunodeficiency Virus) and 
Hepatitis C virus which can lead to the higher risk of development of cancer in the 
liver (Merchante et al., 2013). There have been studies which showed EBV and HPV 
co-infection in various diseases. Study in anogenital warts showed that HPV DNA 
sequences were detected more often in HIV positive patients. EBV infection was also 
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observed, however no association was found with other viruses (Bernard et al., 1992). 
Bernard et al suggested that HPV co-infection may be associated with the neoplastic 
transformation of anogenital lesions. HPV and EBV co-infection was also found in 
HIV infected and also renal transplant oral healthy mucosa (Ammatuna et al., 2001). 
It was suggested that HPV and EBV co-infection may increase the risk for 
development of oral premalignant and malignant lesions. Besides viruses, EBV was 
also found to co-infect with bacteria such as Helicobacter pylori to cause severe 
gastritis in paediatric patients, which may increase the risk of the development of 
more serious lesions in later life (Cardenas-Mondragon et al., 2013). The importance 
of viral co-infection in cancer development prompted us to study the two main 
viruses which are thought to be involved in NPC i.e. EBV and HPV. EBV and HPV 
co-infection in NPC have been reported in various studies around the world (Laantri 
et al., 2011, Maxwell et al., 2010, Punwaney et al., 1999, Dogan et al., 2013). 
However, no reports are available on HPV and its co-infection in Malaysian NPC. 
 
1.6 EBV LMP-1 
EBV latent membrane protein 1 (LMP-1) is a viral protein associated with Epstein-
Barr virus, abundantly expressed in EBV infected cells and functions as a key protein 
in B cell transformation and immortalization (Cahir McFarland et al., 1999). EBV 
mediated B-cell proliferation is also dependent on this particular protein by the 
activation of CD40 receptor. (Kilger et al., 1998). LMP-1 is a 66kDA integral 
membrane protein. It is comprised of a short amino acid cytoplasmic N-terminus 
(amino acids 1-23), six hydrophobic alpha-helical transmembrane spanning regions 
(amino acids 24–186) and a large 200 amino acid cytoplasmic C-terminal tail (amino 
acids 187–386) (Dawson et al., 2012). 
